Ads
related to: astrazeneca fasenra- Eosinophil Diseases
Learn About A Treatment For
Multiple Eosinophil-Driven Diseases
- Adverse Reaction Info
Explore Safety Information For
A Severe Asthma Treatment.
- Prescribing Information
Get Prescribing Information For A
Severe Eosinophilic Asthma Therapy.
- Clinical Trial Data
View Clinical Trial Data For A
Severe Eosinophilic Asthma Med.
- Eosinophil Diseases
Search results
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
Zacks via Yahoo Finance· 1 month agoAstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra...
AstraZeneca's Fasenra Flunks Late-Stage Trial In Patients With Esophagus Inflammation
Benzinga via Yahoo Finance· 2 years agoAstraZeneca Plc (NASDAQ: AZN) has reported topline data from the MESSINA Phase 3 trial Fasenra...
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
Zacks via Yahoo Finance· 2 days agoAstraZeneca AZN announced its long-term plan to generate $80 billion in total revenues by 2030,...
AstraZeneca (AZN) Key Drugs to Aid Growth, Pipeline Strong
Zacks via Yahoo Finance· 8 months agoAstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Fasenra and Farxiga should keep driving...
AstraZeneca’s Fasenra: Approval for asthma may initiate COPD approval
Pharmaceutical Technology via Yahoo Finance· 3 weeks agoAstraZeneca has recently announced that Fasenra has been approved for severe asthma, specifically...
AstraZeneca (AZN) Q1 Earnings Beat, COVID Products Hurt Sales
Zacks via Yahoo Finance· 1 year agoAstraZeneca’s AZN first-quarter 2023 core earnings of 96 cents per American depositary share (ADS)...
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
Zacks via Yahoo Finance· 4 weeks agoAstraZeneca’s AZN first-quarter 2024 core earnings of $1.03 per American depositary share (ADS) beat...
AstraZeneca (AZN) Beats on Q3 Earnings & Sales, Ups 2023 View
Zacks via Yahoo Finance· 6 months agoAstraZeneca’s AZN third-quarter 2023 core earnings of 87 cents per American depositary share (ADS)...
AstraZeneca (AZN) Q2 Earnings & Sales Beat, Nil COVID Sales
Zacks via Yahoo Finance· 10 months agoAstraZeneca (AZN) beats second-quarter estimates for earnings and sales. The company did not...
AstraZeneca sets sights on $80B in revenue by 2030
BioPharma Dive via Yahoo Finance· 2 days agoA decade ago, as British drugmaker AstraZeneca fought off a hostile takeover bid by Pfizer, CEO Pascal Soriot made a big promise: The company, he said,...
Ads
related to: astrazeneca fasenra